ICP-723 not checked

Beijing InnoCare Pharma Tech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ICP-723 tablet administered orally,once a day,for every 28 days as one cycle”In the company’s words, NCT05745623 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion, Solid Tumors
Main trialPhase 1/2
“A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors”In the company’s words, NCT05745623 on ClinicalTrials.gov

Other drugs for Solid Tumors

All 2438 drugs for Solid Tumors

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting 25 Dec 2027 Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Phase 1/2Recruiting 25 Jan 2028 A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Phase 1Unknown Nov 2023 Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ICP-723

Following is part of Solo: you see every change to ICP-723 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in